Dr. Neal Patel says biopsy results may not fully capture prostate cancer risk, stressing that PSA, stage and disease volume should also guide treatment. Biopsy results alone may not fully capture the ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

Prostate-specific antigen (PSA) screening for prostate cancer (PCa) remains highly controversial, largely because it is unclear whether the primary benefits of reducing rates of metastases and cancer ...

People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...

A new study reveals that some men who are diagnosed with “Grade Group one” (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell ...

Two international genitourinary pathology societies have published a white paper calling for improvements in the detection and diagnosis of indolent prostate cancers (PCs). According to the new ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

From 2010 to 2024, the rate of surgeries declined more than fivefold in patients with pathologic grade group 1 (pGG1) prostate cancer, a cohort study found. The small proportion that were performed ...

Some cancers may not require immediate treatment, from prostate cancer to thyroid tumors. Medical experts share when ...

CLEVELAND, Ohio — A recent study led by Cleveland-area researchers suggests that prostate cancers classified as low risk may not be as low risk as previously thought. The study included researchers ...